Thalassemia is a fatal genetic blood disease that is a worldwide public health problem. Despite some improvement in supportive care, limited advances have occurred in the treatment of patients. This proposal describes the California Thalassemia Center (CTC) and its proposed clinical research studies. In California there has been a rapid growth in the number of thalassemia patients because of the large immigration of at-risk people of Asian descent. This has led to thalassemia variants being the most common finding in the California newborn screening program. The CTC presently cares for 206 patients, including 163 patients in the northern center and 43 patients at the recently developed Los Angeles satellite. There are 80 chronically transfused patients and 126 thalassemia intermedia patients. The most common genotypes are Beta-0 thalassemia and E- Beta thalassemia. The Northern California Thalassemia Center was established in 1991 to provide multi-disciplinary care from primary though tertiary service. Integrated into the thalassemia team are subspecialty services including bone marrow transplantation, endocrinology, osteoporosis, cardiology, GI, genetics, psychosocial and primary care. The team meets regularly to review each patient's status and develop a prospective clinical plan. Families are also offered informed opportunities to participate in clinical research. The Thalassemia Coordinating Center is located at Children's Hospital Oakland (CHO) with outreach satellites and includes a specialty outpatient unit, ambulatory transfusion unit, and clinical research center. An adjacent Children's Hospital Oakland Research Institute is dedicated to hemoglobin studies and has a DNA lab, membrane lab, and an iron center (a SQUID is being built). The program has successful experience leading clinical trials in thalassemia, which provides the foundation for the three studies proposed. All three studies have been reviewed for collaborative support and feasibility analysis with thalassemia centers in the US. The first study addresses the problem of accurate measurement of iron burden. It compares new noninvasive technology (New Generation SQUID, MRI and CT) with the gold standard of liver biopsy. The second proposal is designed to determine whether chimeric stem cell transplant is a safe and effective therapy for high-risk thalassemia patients. The third project is a short-term demonstration project on the feasibility and value of setting up an umbilical cord blood program for thalassemia with thalassemia centers across the US. In summary, the CTC has experience, a comprehensive infrastructure, the patient population, and research studies needed to reach the goals of the Thalassemia Clinical Research Network.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HL065239-05
Application #
6760190
Study Section
Special Emphasis Panel (ZHL1-CSR-C (M1))
Program Officer
Moore, Robert Blaine
Project Start
2000-07-01
Project End
2005-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
5
Fiscal Year
2004
Total Cost
$326,812
Indirect Cost
Name
Children's Hospital & Res Ctr at Oakland
Department
Type
DUNS #
076536184
City
Oakland
State
CA
Country
United States
Zip Code
94609
Morris, Claudia R; Kim, Hae-Young; Klings, Elizabeth S et al. (2015) Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. Br J Haematol 169:887-98
Tubman, Venée N; Fung, Ellen B; Vogiatzi, Maria et al. (2015) Guidelines for the Standard Monitoring of Patients With Thalassemia: Report of the Thalassemia Longitudinal Cohort. J Pediatr Hematol Oncol 37:e162-9
Green, Sage T; Martin, Marie B; Haines, Dru et al. (2014) Variance of pain prevalence and associated severity during the transfusion cycle of adult thalassaemia patients. Br J Haematol 166:797-800
Porter, John B; Wood, John; Olivieri, Nancy et al. (2013) Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson 15:38
Haines, Dru; Martin, Marie; Carson, Susan et al. (2013) Pain in thalassaemia: the effects of age on pain frequency and severity. Br J Haematol 160:680-7
Oliveros, Olivia; Trachtenberg, Felicia; Haines, Dru et al. (2013) Pain over time and its effects on life in thalassemia. Am J Hematol 88:939-43
Walter, Patrick B; Porter, John; Evans, Patricia et al. (2013) Increased leucocyte apoptosis in transfused ?-thalassaemia patients. Br J Haematol 160:399-403
Thompson, Alexis A; Kim, Hae-Young; Singer, Sylvia T et al. (2013) Pregnancy outcomes in women with thalassemia in North America and the United Kingdom. Am J Hematol 88:771-3
Kwiatkowski, Janet L; Kim, Hae-Young; Thompson, Alexis A et al. (2012) Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood 119:2746-53
Trachtenberg, Felicia L; Martin, Marie; Green, Sage et al. (2012) Use of electronic data collection to assess pain in thalassaemia: a feasibility study. Int J Palliat Nurs 18:441-5

Showing the most recent 10 out of 22 publications